

Oregano Essential Oil: An Effective and Non-Toxic Approach for prevent or treat Resistant *Candida* Species

Liliana Fernandes^{1(*)}, Inês Silva¹, Elena Blázquez², Ainara Tejada^{2,3}, Artur Ribeiro^{1,4}, Sónia Silva^{1,4}, Nuno Mira⁵, Lorena Cussó^{3,6}, Sofia Costa-de-Oliveira⁷, Mariana Rodrigues^{1,4}, Mariana Henriques^{1,4}

¹Centre of Biological Engineering, University of Minho, Braga, Portugal; ²Medical Imaging Laboratory, Medicine and Experimental Surgery Unit, Gregorio Marañón General University Hospital, Gregorio Marañón Health Research Institute, Madrid, Spain; ³Department of Bioengineering, University Carlos III of Madrid, Madrid, Spain; ⁴LABBELS – Associate Laboratory, Braga/ Guimarães, Portugal; ⁵Instituto Superior Técnico, Department of Bioengineering, Instituto Superior Técnico, University of Lisbon, Lisbon, Portugal; ⁶Advanced Imaging Unit, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; ⁷Division of Microbiology, Department of Pathology, Faculty of Medicine, University of Porto, Portugal; Center for Health Technology and Service Research – CINTESIS@RISE, Faculty of Medicine, University of Porto, Porto, Portugal.



Introduction

Vulvovaginal candidiasis (VVC) is a prevalent vaginal infection, with drug-resistant *Candida* strains representing a growing treatment challenge^{1,2}. *Candida albicans* and *Candida glabrata* are particularly resistant to azoles, are the most frequently found species³. Traditional antifungal agents like azoles, polyenes and echinocandin are becoming less effective, making the discovery of effective alternative therapies crucial¹. In this sense, oregano essential oil (OEO) has emerged as a promising alternative due to its antimicrobial properties, with the ability to inhibit *Candida* biofilms, a key factor in resistance⁴. Recent studies have shown that the vapor phase of essential oils (VP-EOs) has greater antimicrobial activity than the liquid phase⁵. However, the effectiveness of essential oils (EOs) is influenced by factors such as photosensitivity, high volatility, low water miscibility, and degradability at higher temperatures, reducing bioavailability.




Goal of the study


- Evaluation of the vapor phase of oregano EO (VP-OEO) effect on biofilms of antifungal-resistant *Candida* species (*C. albicans* and *C. glabrata*) and determine their mode of action. Furthermore, a reconstituted human vaginal epithelium (RHVE) was used to mimic vaginal conditions and evaluate the effect of this therapy on *Candida* infection.
- In vitro* and *in vivo* evaluation of the effect of microparticles (KMPs) loaded with oregano essential oil (OEO-KMP's) for the *C. albicans* infection treatment.

Methods

Effect of VP-OEO



Effect of OEO-KMP's



Results




Figure 1. Effect of the VP-OEO on the biofilm formation and pre-formed biofilm of *C. albicans* and *C. glabrata*, evaluated from (A) time-killing assay, (B) cell viability and (C) metabolic activity (SI).




Figure 2. Confocal Laser Scanning Microscopy images of (A) *C. albicans* biofilms and (B) *C. glabrata* biofilms after 12 h of VP-OEO. CLSM images show the staining pattern for live cells (green) and dead cells (red).




Figure 3. VP-OEO effect on *C. albicans* and *C. glabrata* species infection of the RHVE after 24 h (A) RHVE images showing *Candida* infection and VP-OEO effect; (B) *Candida* infection of the RHVE (log CFU per milliliter); (C) Relative lactate dehydrogenase (LDH) activity measured in the RHVE supernatant after incubation with the *Candida* strains compared to the untreated epithelium and effect of VP-OEO compared to simulated vaginal fluid. * indicate a statistically significant reduction in comparison with the respective control (** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$).




Figure 4. Effect, *in vitro*, of the OEO-KMP's on (A) single and mixed infection of (B) *C. albicans* with (C) *Lactobacillus gasseri*. * indicate statistical reduction of biofilms cell cultivability in comparison with the respective control (** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$).




Figure 5. Mice model of vaginal candidiasis. (A) Timeline of *albicans* infection and OEO-KMP's treatment of mice models; (B) M weight according to the timeline of infection; (C) *C. albicans* and *Lactobacillus* species in mice vaginal lavage fluid (* $p < 0.05$); Histopathology of vaginal tissue from mice with no *C. albicans* and *C. albicans* infection and OEO-KMP's exposure. (a) layer of superficial squamous epithelial cells, (b) basal membrane, (c) submucosa, (d) *albicans* cell and (e) neutrophils. The results were registered under 1 and 20 \times magnification.

The study showed potent antifungal activity of the VP-OEO against two drug-resistant *Candida* isolates:
 ✓ Flow cytometry analysis indicated that VP-EO's mechanisms of action involve altering membrane integrity and decreasing metabolic activity.
 ✓ The epithelial model confirms the VP-OEO's, with LDH activity levels showing no significant effect on RHVE compared to the control.

The OEO-KMP's effectiveness, *in vitro* and *in vivo*, against *C. albicans* infection were confirmed:
 ✓ This therapy keeps the microflora intact, specifically in terms *Lactobacillus* species.

Main conclusion

These studies highlight the promising efficacy of **Oregano essential oil** as an alternative for VVC treatment. Both approaches, **VP-OEO** and **OEO-KMP's**, showed effective antifungal activity against drug-resistant strains while preserving vaginal health. These therapeutic options not only combat antifungal resistance, but also potentially propose a safer option for women's health due to their natural characteristics.

References

- Prestinaci F, Pezzotti P, Pantosti A. 2015. Antimicrobial resistance: a global multifaceted phenomenon. *Pathog Glob Health* 109: 309–318.
- Denning, D. W., Kneale, M., Sobel, J. D. & Rautema-Richardson, R. 2018. Global burden of recurrent vulvovaginal candidiasis: a systematic review. *The Lancet Infectious Diseases* vol. 18 e339–e347.
- Brunk S, Hube B. 2013. Two unlike cousins: *Candida albicans* and *C. glabrata* infection strategies. *Cell Microbiol* 15: 701–708.
- Hacıoglu, M., Oyadı, O. & Kirinti, A. 2021 Oregano essential oil inhibits *Candida* spp. biofilms. *Zeitschrift für Naturforschung - Section C Journal of Biosciences* 76: 443–450.
- Feyereis, A. F. et al. 2018. Essential oils and their components are a class of antifungals with potent vapour-phase-mediated anti-*Candida* activity. *Scientific Reports* 8: 1–10.

Acknowledgements

This study was supported by the Portuguese Foundation for Science and Technology under the scope of the strategic funding of UIDB/04469/2020 unit and 2020.05720.3D for Liliana Fernandes. Also, this study was supported by LAF Associate Laboratory in Biotechnology, Bioengineering and Microelectronics Systems, LA/P/0029/2020 and Maria Elisa Rodrigues thanks FCT for funding program DL 57/2016—Norma transitória. Sofia Costa de Oliveira acknowledges funds through FCT, I.P., within the scope of the project "RISE - LA/P/0053/2020. Pereira Mira acknowledges support from FCT through its funding of research in *Candida-lactobacilli* interactions through LactoCan project (contract number: PT/MIC/1515/2017), IBB (contract: UIDB/04565/2020) and IBB funding LA/P/0140/2020). Lorena Cussó acknowledges support by Agencia Estatal de Investigación (PR2020-095268 MCIN / AEI / 10.13039/501100011033 and by "ERDF Investing future", by Instituto de Salud Carlos III (PT20/0004) and co-funded by European (ERDF) "A way to make Europe".